Recent advances in the development of new treatments for celiac disease

Bibliography

• Dicke W, Weijers H, van deKamer J. Coelic disease.II. The presence in wheat having a deleterious effect in cases of coeliac disease. Acta Paediatr 1953;42:34-42
   PubMedGoogle Scholar
• Rashtak S, Murray J. Review article: coelic disease, new approaches to therapy. Aliment Phrmacol Ther 2012;35:768-81
   PubMed Web of Science ®Google Scholar
• Scanlon Murray JA. Update on celiac disease - etiology, differential diagnosis, drug targets, and management advances. Clin Exp Immunol 2011;4:297-311
   Google Scholar
• Sollid l, Khosla C. Novel therapies for coeliac disease. J Intern Med 2011;269:604-13
   PubMed Web of Science ®Google Scholar
• Selimoglu MA, Karabiber H. Celiac disease, prevention and treatment. J Clin Gastroenterol 2010;44:4-8
   PubMed Web of Science ®Google Scholar
• Lionetti E, Catassi C. New clues in celic disease epidemiology, pathogenesis, clinical manifestations and treatment. Int Rev Immunol 2011;30:219-31
   PubMed Web of Science ®Google Scholar
• Marietta EV, David CS, Murray JA. Important lesson derived from animal models of celiac disease. Int Rev Immunol 2011;30:197-206
   PubMed Web of Science ®Google Scholar
• Donnelly SC, Ellis HJ, Ciclitira PJ. Pharmacotherapy and management strategies in celiac disease. Expert Opin Pharmacother 2011;12:1731-44
   PubMed Web of Science ®Google Scholar
• Rodrigo L. Investigational therapies for celiac disease. Expert Opin Investig Drugs 2009;18:1865-73
   PubMed Web of Science ®Google Scholar
• Perez L, de Villasante G, Ruiz A, Leon F. Non-dietary therapeutic clinical trials in celiac disease. Eur J Int Med2011;23:9-14
   PubMed Web of Science ®Google Scholar
• Lerner A. New therapeutic strategies for celiac disease. Autoimmun Rev 2010;9:144-7
   PubMed Web of Science ®Google Scholar
• Tennyson C, Lewis S, Green P. New and developing therapies for celiac disease. Ther Adv Gastroenterol 2009;2:303-9
   PubMedGoogle Scholar
• Sanz Y. Novel perspectives in celiac disease therapy. Mini Rev Med Chem 2009;9:359-67
   PubMed Web of Science ®Google Scholar
• Anderson RP. Coeliac disease: current approach and future prospects. Int Med J 2008;38:790-9
   Google Scholar
• Baldassarre M, Laneve AM, Grosso R, Celiac disease: pathogenesis and novel therapeutic strategies. Endocr Metab Immune Disord Drug Targets 2008;8:152-8
   PubMedGoogle Scholar
• Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009;137:1912-33
   Google Scholar
• Armstrong MJ, Robins GG, Howdle PD. Recent advances in coeliac disease. Curr Opin Gastroenterol 2009;25:100-9
   Google Scholar
• Aziz I, Evans KE, Papageorgiou V, Are patients with coeliac disease seeking alternative therapies to a gluten-free diet? J Gastrointestin Liver Dis 2011;20:27-31
   PubMed Web of Science ®Google Scholar
• Husby S, Koletzko S, Korponay-Szabo IR, ESPGHAN working group on coeliac disease diagnosis; ESPGHAN Gastroenterology committee. european society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012;54:136-60
   PubMed Web of Science ®Google Scholar
• Bardella MT, Velio P, Cesana BM, Coelic disease: a histological follow-up study. Histopathology 2007;50:465-71
   PubMed Web of Science ®Google Scholar
• Midhagen G, Hallert C. High rate of gastrointestinal symptoms in celiac patients living on a gluten-free diet: controlled study. Am J Gastroenterol 2003;98:2023-6
   PubMed Web of Science ®Google Scholar
• Murray J, Watson T, Clearman B, Effect of gluten-free diet on gastrointestinal symptoms in celiac disease. Am J Clin Nutr 2004;79:669-73
   PubMed Web of Science ®Google Scholar
• Kaukinen K, Peraaho M, Lindfors K, Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. Aliment Pharmacol Ther 2007;15:1237-45
   Google Scholar
• Rubio-Tapia A, Rahim MW, See JA, Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol 2010;105:1412-20
   PubMed Web of Science ®Google Scholar
• Dewar DH, Donnelly SC, McLaughin SD, Celiac disease: management of persistent symptoms in patients on a gluten-free diet. World J Gastroenterol 2012;18:1348-56
   PubMed Web of Science ®Google Scholar
• Shewry P, Tatham A, Kasarda D. Cereal proteins and celiac disease. In: Marsh M, editor, Coeliac disease, Blackwell Scientific Publications, Oxford; 1992. p. 305-48
   Google Scholar
• Kasarda DD, Autran A-C, Lew E, N-terminal amino acid sequences of omega–gliadins and omega-secalins implications for the evolution of prolamin genes. Biochim Biophys Acta 1983;747:138-50
   Web of Science ®Google Scholar
• Kasarda D, Okita T, Bernardin J, Nucleic acid (cDNA) and amino acid sequences of alpha-type gliadins from wheat (Triticum aestivum). Proc Natl Acad Sci USA 1984;81:4712-16
   PubMed Web of Science ®Google Scholar
• Spaenij-Dekking L, Kooy-Winkelaar Y, van Veelen P, Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastoenterology 2005;129:797-806
   PubMed Web of Science ®Google Scholar
• Hausch F, Shan L, Santiago N, Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 2002;283:G996-1003
   PubMed Web of Science ®Google Scholar
• Shan L, Molberg O, Parrot I, Structural basis for gluten intolerance in celiac sprue. Science;2002;297:22
   Google Scholar
• Fasano A, Uzzau S. Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J Clin Invest 1997;99:1158-64
   PubMed Web of Science ®Google Scholar
• Drago S, Al Asmar R, Di Pierro M, Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006;41:408-19
   PubMed Web of Science ®Google Scholar
• Tripathi A, Lammers KM, Goldblum S, Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA 2009;106:16799-804
   PubMed Web of Science ®Google Scholar
• Nilsen EM, Lundin KEA, Kracji P, Gluten specific, HLA-restricted T cells from celiac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut 1995;37:766-76
   PubMed Web of Science ®Google Scholar
• Abadie V, Sollid LM, Barreiro LB, Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Ann Rev Immunol 2011;23:493-525
   Google Scholar
• Maki M. The humoral immune system in coeliac disease. Baillieres Clin Gastroenterol 1995;9:231-49
   PubMed Web of Science ®Google Scholar
• Lindfors K, Maki M, Kaukinen K. Transglutaminase 2-targeted autoantibodies in celiac disease: pathogenic players in addition to diagnostic tools? Autoimm Rev 2010;9:744-9
   PubMed Web of Science ®Google Scholar
• Maiuri L, Ciacci C, Ricciardelli I, Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 2003;362:30-7
   PubMed Web of Science ®Google Scholar
• Jabri B, Patey-Mariaud de Serre N, Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 2000;118:867-9
   PubMed Web of Science ®Google Scholar
• Hogberg L, Stenhammar L, Wagermark J. Very late mucosal relapse in a girl with coeliac disease. Acta Paediatr 1993;82:887-9
   PubMed Web of Science ®Google Scholar
• Matysiak-Budnik T, Malamut G, Patey-Mariaud de Serre N, Long- term follow-up of 61 patients diagnosed in childhood: evolution towards latency is possible on a normal diet. Gut 2007;56:1379-86
   PubMed Web of Science ®Google Scholar
• Kurppa K, Koskinen O, Collin P, Changing phenotype of celiac disease after long-term gluten exposure. J Pediatr Gastroenterol Nutr 2008;47:500-3
   PubMed Web of Science ®Google Scholar
• Holm K, Maki M. Vuolteenaho et al. Oats in the treatment of childhood coeliac disease: a two year controlled and a long-term clinical follow-up study. Aliment Pharmacol Ther 2006;23:1463-72
   PubMed Web of Science ®Google Scholar
• Maki M, Lahdeaho ML, Hallstrom O, Postpubertal gluten challenge in coeliac disease. Arch Dis Child 1989;64:1604-7
   PubMed Web of Science ®Google Scholar
• van Overbeek FM, Uil-Dieterman IG, Mol IW, The daily gluten intake in relatives of patients with coeliac disease compared with that of general Dutch population. Eur J Gastroenterol Hepatol 1997;9:1097-9
   Google Scholar
• Kumar P, Walker-Smith J. MillaP et al. The teenage coeliac: a follow up study of 102 patients. Arch Dis Child 1988;63:916-20
   PubMed Web of Science ®Google Scholar
• Montgomery A, Goka A, Kumar P, Low gluten diet in the treatment of adult celiac disease: effect on jejunal morphology and serum anti-gluten antibodies. Gut 1988;29:1564-8
   PubMed Web of Science ®Google Scholar
• Catassi C, Fabiani E, Iacono G, A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007;85:160-6
   PubMed Web of Science ®Google Scholar
• Lahdeaho ML, Maki M, Laurila K, Small-bowel mucosal changes and antibody responses after low-and moderate dose gluten challenge in celiac disease. BMC Gastroenterol 2011;11:129
   PubMed Web of Science ®Google Scholar
• Bethune MT, Khosla C. Oral enzyme therapy for celiac sprue. Meth Enzymol 2012;502:241-71
   PubMed Web of Science ®Google Scholar
• Siegel M, Bethune M. Rational design of combination enzyme therapy for celiac sprue. Chem Biol 2006;13:649-58
   PubMed Web of Science ®Google Scholar
• Siegel M, Garber ME, Spencer AG, Safety, tolerability, and activity of ALV003: results from the phase 1 single escalating – dose clinical trials. Dis Dis Sci 2012;57:440-50
   PubMed Web of Science ®Google Scholar
• Lahdeaho M-L, Kaukinen K, Laurila K, A novel glutenase attenuates gluten-induced small intestinal mucosal injury in coelic disease patients: a randomized controlled Phase 2 clinical trial. Gut 2011;60:A12
   Google Scholar
• Shan L, Marti T, Sollid L, Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for celiac sprue. Biochem J 2004;383:311-18
   PubMed Web of Science ®Google Scholar
• Stepniak D, Spaenij-Dekking L, Mitea C, Highly efficient gluten degradation with a newly identified prolyl endopeptidase: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol 2006;291:G621-9
   PubMed Web of Science ®Google Scholar
• Mitea C, Havenaat R, Drijfhout JW, Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 2008;57:25-32
   PubMed Web of Science ®Google Scholar
• Tack G, van de Water J, Kooy-Winkelaar E, Can prolyl endopeptidase enzyme treatment mitigate the toxic effect of gluten in coeliac patients? Gastroenterology 2010;S54
   Google Scholar
• Collado MC, Isolauri E, Salminen S, Sanz Y. The impact of probiotics on gut health. Curr Drug Metab 2009;10:68-78
   PubMed Web of Science ®Google Scholar
• Szajweska H, Wanke M, Patro B. Meta-analysis: the effects of Lactobacillus rhamnosus GG supplementation for the prevention of healthcare-associated diarrhoea in children. Alimentary Pharmacol Ther 2011;34:1079-87
   PubMed Web of Science ®Google Scholar
• Gobbetti M, Giuseppe Rizzello C, Sourdough lactobacilli and celiac disease. Food Microbiol 2007;24:187-96
   PubMed Web of Science ®Google Scholar
• Greco L, Gobbetti M, DiMase R, Safety for patients with celiac disease of baked goods made with wheat flour hydrolyzed during food processing. Clin Gastroenterol Hepatol 2011;9:24-9
   PubMed Web of Science ®Google Scholar
• Lindfors K, Blomqvist T, Juuti-Uusitalo K, Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol 2008;152:552-8
   PubMed Web of Science ®Google Scholar
• Cinova J, De Palma G, Stepankova R, Role of intestinal bacteria in gliadin-induced changes in intestinal mucosa: study in germ-free rats. PLoS One 2011;6:e16169
   PubMed Web of Science ®Google Scholar
• Zamakhchari M, Wei G, Dewhirst F, Identification of Rothia bacteria as gluten-degrading natural colonizers of the upper gastro-intestinal tract. PLoS One 2011;6:e24455
   PubMed Web of Science ®Google Scholar
• Pinier M, Verdu EF, Nasser-Edine M, Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 2009;135:288-98
   Google Scholar
• Pinier M, Fuhrmann G, Galipeau HJ, The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 2012;142:316-25
   PubMed Web of Science ®Google Scholar
• Fasano A, Not T, Wang W, Zonulin, a newly discovered modulator of intestinal permeability, and its expression in celiac disease. Lancet 2000;355:1518-19
   PubMed Web of Science ®Google Scholar
• Drago S, El Asmar R, DiPierro M, Gliadin, zonulin and gut permeability: effects on coelic disease and non-coeliac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006;41:408-19
   PubMed Web of Science ®Google Scholar
• Wang W, Uzzau S, Goldblum SE, Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci 2000;113:4435-40
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan S, Durai M, Kitchens K, Larazotide regulates epithelial tight junctions in vitro and in vivo. Peptides 2012;35:86-94
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan S, Tripathi A, Tamiz A, Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides 2012;35:95-101
   PubMed Web of Science ®Google Scholar
• Paterson B, Lammers K, Arrieta A, The safety, tolerance, pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007;26:757-66
   PubMed Web of Science ®Google Scholar
• Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 2008;205:143-54
   PubMed Web of Science ®Google Scholar
• Badarau E, Collighan RJ, Griffin M. Recent advances in the development of tissue transglutaminase 2 (TG2) inhibitors. Amino Acids 2011; published online 13 December 2011; doi 10.1007/s00726-011-1188-4
   PubMed Web of Science ®Google Scholar
• Molberg O, Mcadam SN, Korner R, Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998;4:713-17
   PubMed Web of Science ®Google Scholar
• Molberg O, McAdam S, Lundin KE, T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol 2001;31:1317-23
   PubMed Web of Science ®Google Scholar
• Maiuri L, Ciacci C, Ricciardelli I, Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 2005;129:1400-13
   PubMed Web of Science ®Google Scholar
• Kim CY, Quarsten H, Bergseng E, Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 2004;101:4175-9
   PubMed Web of Science ®Google Scholar
• Xia J, Bergseng E, Fleckenstein B, Cyclic and dimeric gluten peptide analogues inhibiting DQ-mediated antigen presentation in celiac disease. Bioorg Med Chem 2007;15:6565-73
   PubMed Web of Science ®Google Scholar
• Juse U, van de Wal Y, Koning F, Design of high-affinity peptide ligands for human leucocyte antigen-DQ2 using a positional scanning peptide library. Hum Immunol 2010;71:475-81
   PubMed Web of Science ®Google Scholar
• Kapoerchan V, Wiesner M, Hillaert U, Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ molecule. Mol Immunol 2010;47:1091-7
   PubMed Web of Science ®Google Scholar
• Tye-Din JA, Stewart JA, Dromey JA, Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med 2010;2:41ra51
   PubMed Web of Science ®Google Scholar
• Brown G, Daveson J, Marjason JK, A phase 1 study to determine safety, tolerability and bioactivity of Nexvax® in HLADQ2+volunteers with celiac disease following a long term, strict gluten-free diet. Gastroenterology 2011;140:S437-8
   Web of Science ®Google Scholar
• DavesonA Jones D, Gaze S, Effect of hookworm infection on wheat challenge in Celiac disease – a randomised double-blinded placebo controlled trial. PLoS One 2011;6:e17366
   PubMedGoogle Scholar
• Nissen EM, Lundin KE, Krajci P, Gluten specific, HLA-restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut 1995;37:766-76
   PubMed Web of Science ®Google Scholar
• Mention J, Ben Ahmed M, Begue B, Interleukin 15: a key to distrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003;125:730-45
   PubMed Web of Science ®Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59
   PubMed Web of Science ®Google Scholar
• Reinisch W, de Villiers W, Bene L, Fontolizumab in moderate to severe Crohn´s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple dose study. Inflamm Bowel Dis 2002;16:233-42
   Google Scholar
• Corte C, Saxena P, Tattersall S, When to Use Biological Agents in Inflammatory Bowel Disease. J Gastroenterol Hepatol 2011; published online 21 December 2011; doi:10.1111/j.1440-1746.2011.07056.x
   Web of Science ®Google Scholar
• Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammapharmacology 2012;20:1-18
   PubMedGoogle Scholar
• Malamut G, Machhour R, Montcuquet N, IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease –associated inflammation and lymphomagenesis. J Clin Invest 2010;120:231-43
   Google Scholar
• 93. Dafik L, Albertelli M, Stamnaes J, Activation and inhibition of transglutaminase 2 in mice. Plos One 2012;7:e30624
   PubMedGoogle Scholar
• Sollid L, Molberg O, McAdam S, Autoantibodies in coeliac disease: tissue transglutaminase – guilt by association? Gut 1997;41:851-2
   PubMed Web of Science ®Google Scholar
• Eksteen B, Adams DH. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. Drugs 2010;13:472-781
   PubMed Web of Science ®Google Scholar
• Festen EA, Szperl AM, Weersma RK, Inflammatory bowel disease and celiac disease: overlaps in the pathology and genetics, and their potential drug targets. Endocr Metab Immune Disord Drug Targets 2009;9:199-218
   PubMedGoogle Scholar
• Ciacci C, Maiuri L, Russo I, Efficacy of budesonide therapy in the early phase treatment of adult celiac disease patients with malabsorption: an in vivo (in vitro pilot) study. Clin Exp Pharmacol Physiol 2009;36:1170-6
   PubMed Web of Science ®Google Scholar
• Ryan BM, Kelleher D. Refractory celiac disease. Gastroenterology 2000;119(1):243-51
   PubMed Web of Science ®Google Scholar
• Abdulkarim AS, Burgart LJ, See J, Etiology of nonresponsive celiac disease: results of systematic approach. Am J Gastroenterol 2002;97:2016-21
   PubMed Web of Science ®Google Scholar
• Daum S, Ipczynski R, Heine B, Therapy with budesonide in patients with refractory sprue. Digestion 2006;73:60-8
   PubMed Web of Science ®Google Scholar
• Brar P, Lee S, Lewis S, Budesonide in the treatment of refractory celiac disease. Am J Gastroenterol 2007;102:2265-9
   PubMed Web of Science ®Google Scholar
• Gianfrani C, Siciliano RA, Facchiano AM, Transamidation of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease. Gastroenterology 2007;133:780-9
   PubMed Web of Science ®Google Scholar
• Utech M, Ivanov AI, Samarin SN, Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. Mol Biol Cell 2005;16:5040-52
   PubMed Web of Science ®Google Scholar